Publisher Correction: CRISPR target prediction remains blunt tool for clinical applications.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30894681.
- Also identified by DOI 10.1038/s41587-019-0107-1.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the version of this article initially published, we reported that Sangamo's SB-318 had failed to change baseline leukocyte α-L-iduronidase in a phase 1/2 trial. The drug failed to change baseline plasma α-L-iduronidase but did increase leukocyte α-L-iduronidase to within the normal range. The error has been corrected in the HTML and PDF versions of the article.